Table 3 Medication outcomes of included studies
Authors | Medication outcomes |
|---|---|
Aharaz A. [22] | Differences in deprescribing rates for patients in the intervention versus control group with > 1 medication deprescribed |
Change in total number of medications | |
Percentage of deprescribed medications and sustained | |
Ashworth N. [23] | Mean number of older patients prescribed high dose of BZD |
Mean defined daily dose of BZD | |
Balsom C. [24] | Change in the number of prescribed regular and as-needed medications |
Campbell NL. [27] | Proportion of anticholinergic orders prescribed as discontinuation orders in the preintervention and postintervention periods |
Population prevalence of anticholinergic use | |
Cateau D. [28] | Number of PIMs used |
Number of chronic drugs | |
Number of inappropriate defined daily dose | |
Number of chronic defined daily dose | |
Cateau D. [29] | Proportion of galenic units considered potentially inappropriate at the follow up |
Number of PIMs per day (defined daily dose) | |
Number of PIMs per resident (defined daily dose/resident) | |
Number of defined daily dose/resident to avoid and to reevaluate | |
Clyne B. [30] | Proportion of patients with PIP and mean of PIP |
Cool C. [31] | Potentially inappropriate drug prescribing |
Curtin D. [32] | Mean change in the number of long term prescribed medicines |
Changes in prescription of neuroleptic, antipsychotic medications | |
Dalleur O. [33] | Proportion of PIMs discontinued |
Edey R. [34] | Number of discontinued home medications at hospital discharge |
Proportion of medication remaining deprescribing at 30 days after discharge | |
Eveleigh R. [35] | Proportion of patients discontinuation ATD |
Gedde MH. [36] | Mean change in numbers of prescribed psychotropic drugs |
Gulla C. [38] | Number of antihypertensive drugs |
Hah JM. [39] | Time to baseline opioid use |
Time to complete opioid cessation | |
Ee C.[40] | Reduction in the total number of medications |
Needs for deprescribed medications to be restarted or initiation of new symptomatic control medications after deprescribing | |
Kua CH. [42] | Pill burden |
Kuntz JL. [43] | Discontinuation of BZD-related drugs |
Number of Z-drug dispensing | |
Navy HJ. [44] | Composite criteria: - Rate of patients who had no alprazolam dispensing - Rate of patients who had an alprazolam dose reduction - Rate of patients who interchanged to an alternate medication |
Potter K. [45] | Mean change in drugs number |
Mean change in drugs number | |
Rieckert A. [46] | Number of drugs prescribed |
Smeets CHW. [48] | Prescription of psychotropic drugs |
Sullivan MD. [49] | Mean daily opioid dose in the past week at 22 weeks after randomization |
Opioid dose 34 weeks after randomization | |
Percent reduction from baseline in opioid dose | |
Tannenbaum C. [50] | Complete cessation of BZD |
Dose reduction of BZD | |
Tseng ES. [51] | Opioid use on the day prior to discharge |
Percentage of patients who were discharged with prescriptions for opioid or ancillary medications | |
Morphine equivalent doses prescribed at discharge | |
Late prescription and morphine equivalent doses at 30 days | |
Van der Meer HG. [52] | Difference in proportion of patients having a decrease of DBI > 0,5 |
Vicens C. [53] | Discontinuation BZD |
Vicens C. [54] | BZD cessation |
Wong APY. [55] | Percentage reduction of total daily dose of PIMs |
Percentage reduction of total number of medicine of PIMS | |
Medicine reinitialization or substitution | |
Wouters H. [56] | Proportion of resident who successfully discontinued use of at least 1 inappropriate medication |
Number of residents for whom at least 1 underprescribing medication was initiated at least 1 dose was adjusted, and at least 1 potentially hazardous drug was replaced by a safer alternative | |
Cumulative exposure to anticholinergic and sedative drugs | |
Zechmann S. [57] | Mean difference in the number of drugs per person |
Number of drug change recommendations and kind of change | |
Number of DPP taken without the GP knowledge at pre intervention |